DAWN Q1 2025 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M

Gross Profit

$28M90.6% margin

Operating Income

-$41M-133.5% margin

Net Income

-$36M-117.0% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+5.3%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$63M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$534M

Total Liabilities

$55M

Stockholders' Equity

$480M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$0	—
Gross Profit	$28M	-$116,000	+24131.9%
Operating Income	-$41M	-$67M	+38.5%
Net Income	-$36M	-$62M	+42.3%

Revenue Segments

Product

$31M99%

License

$258,0001%